6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $22.00, and a low estimate of $13.00. A decline of 6.67% from the prior average price target is evident in the current average.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Amicus Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Debjit Chattopadhyay | Guggenheim | Announces | Buy | $13.00 | – |
| Karl Chalabala | UBS | Lowers | Buy | $19.00 | $20.00 |
| Jeffrey Hung | Morgan Stanley | Lowers | Overweight | $19.00 | $20.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Buy | $13.00 | $14.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $19.00 | $21.00 |
| Kristen Kluska | Cantor Fitzgerald | Maintains | Overweight | $22.00 | – |
Key Insights:
Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their stance, it reflects their response to recent developments related to Amicus Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from ‘Outperform’ to ‘Underperform’. These ratings reflect expectations for the relative performance of Amicus Therapeutics compared to the broader market.
Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Amicus Therapeutics’s stock. This comparison reveals trends in analysts’ expectations over time.
Navigating through these analyst evaluations…
Click Here to Read the Full Original Article at Cryptocurrencies Feed…
